Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on July 10, 2018, covering events occurring on July 9, 2018. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
On July 9, 2018, CytoSorbents Corporation and Aferetica srl debuted Aferetica's PerLife™ ex-vivo organ perfusion system integrated with CytoSorbents' PerSorb™ adsorber. This demonstration took place at the 27th International Congress of the Transplantation Society in Madrid, Spain.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the announcement of the product demonstration. The full text of the press release regarding this event is included as Exhibit 99.1.
Investor Verification Points
- Review Exhibit 99.1 for the full details of the press release regarding the PerLife™ and PerSorb™ system debut.
- Verify the strategic implications of the partnership with Aferetica srl for future revenue streams.
- Check subsequent filings for any financial impact resulting from the collaboration announced in this report.